Brean Murray, Carret & Co., which initiated InterMune Inc. ITMN at Buy, is providing some color on the stock.
“We are initiating coverage of InterMune with a Buy rating and a $50 price target,” Brean Murray writes. “InterMune is beginning to launch Esbriet, a newly approved drug for the treatment of a fatal disease, idiopathic pulmonary fibrosis, in the European Union. We believe the market opportunity for Esbriet in the EU can speak at $1 billion per year.”
InterMune closed Tuesday at $35.47.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in